Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024
Shots:
- Akeso has featured results from the P-II (AK112-205) trial assessing ivonescimab (PD-1/VEGF bispecific antibody) alone or in addition to CT as a perioperative treatment of resectable NSCLC at WCLC 2024
- The trial, as of Feb 2024, recruited 60 patients (78.3% in stage III & 90% in N+ stage), with 49 of them undergoing R0 resections
- Study depicted pCR rate of 43.6% & MPR rate of 71.8% with 2% of them having residual viable tumor (RVT) <5% with the combination; as of Aug 2024, 55 patients showed pCR rate of 52.7% & MPR rate of 72.7% post-surgery. pCR and MPR rates were 63.6% & 84.1%, respectively, in squamous NSCLC patients. Ivonescimab alone showed pCR rate of 30% & MPR rate of 60%
Ref: Akeso | Image: Akeso
Related News:- Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
